@article{MTMT:34760472,
	title = {Aromatase Inhibitors and Plasma Lipid Changes in Postmenopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis},
	url = {https://m2.mtmt.hu/api/publication/34760472},
	author = {Bérczi, Bálint and Borbásné Farkas, Kornélia and Hegyi, Péter and Tóth, Barbara and Csupor, Dezső and Németh, Balázs and Lukács, Anita and Czumbel, László Márk and Kerémi, Beáta and Kiss, István and Szabó, Andrea and Varga, Gábor and Gerber, Gábor and Gyöngyi, Zoltán},
	doi = {10.3390/jcm13061818},
	journal-iso = {J CLIN MED},
	journal = {JOURNAL OF CLINICAL MEDICINE},
	volume = {13},
	unique-id = {34760472},
	abstract = {Background: Women are typically diagnosed with estrogen receptor-positive breast cancer around the postmenopausal period when declining estrogen levels initiate changes in lipid profiles. Aromatase inhibitors (AI) are used to prevent the progression of cancer; however, a further reduction in estrogen levels may have detrimental effects on lipid levels, which was our working hypothesis. Methods: Our meta-analysis was conducted on the lipid profiles of postmenopausal breast cancer patients at baseline and at different treatment time points. Results: We identified 15 studies, including 1708 patients. Studies using anastrozole (ANA), exemestane (EXE), letrozole (LET), and tamoxifen (TMX) were involved. Subgroup analyses revealed that 3- and 12-month administrations of LET and EXE lead to negative changes in lipid profiles that tend to alter the lipid profile undesirably, unlike ANA and TMX. Conclusions: Our results suggest that, despite statistically significant results, EXE and LET may not be sufficient to cause severe dyslipidemia in patients without cardiovascular comorbidities according to the AHA/ACC Guideline on the Management of Blood Cholesterol. However, the results may raise the question of monitoring the effects of AIs in patients, especially those with pre-existing cardiovascular risk factors such as dyslipidemia.},
	year = {2024},
	eissn = {2077-0383},
	orcid-numbers = {Borbásné Farkas, Kornélia/0000-0002-5349-6527; Hegyi, Péter/0000-0003-0399-7259; Tóth, Barbara/0000-0002-6086-8819; Csupor, Dezső/0000-0002-4088-3333; Németh, Balázs/0000-0002-4914-9872; Lukács, Anita/0000-0002-0746-8920; Czumbel, László Márk/0000-0002-5915-0383; Kerémi, Beáta/0000-0003-4000-9440; Szabó, Andrea/0000-0003-4949-9431; Varga, Gábor/0000-0002-5506-8198; Gerber, Gábor/0000-0003-0256-2608; Gyöngyi, Zoltán/0000-0001-9330-9119}
}

@article{MTMT:34728728,
	title = {Storage Conditions Influence the Quality of Ginger – A Stability Study Inspired by Clinical Trials},
	url = {https://m2.mtmt.hu/api/publication/34728728},
	author = {Tóth, Barbara and Horváth, Attila and Jójártné Laczkovich, Orsolya and Biró, Dalma and Matuz, Mária and Csupor, Dezső},
	doi = {10.1055/a-2283-8147},
	journal-iso = {PLANTA MED},
	journal = {PLANTA MEDICA: NATURAL PRODUCTS AND MEDICINAL PLANT RESEARCH},
	unique-id = {34728728},
	issn = {0032-0943},
	abstract = {Ginger has traditionally been used to treat and prevent nausea and vomiting; however, the results of clinical trials are ambiguous. The efficacy of ginger is attributed to gingerols and their metabolites, shogaols. Since these compounds have different pharmacological profiles, the clinical efficacy of ginger products is largely dependent on their chemical composition. The goal of our study was to examine the stability of ginger determining the 6-gingerol contents in order to assess the effects of different storage conditions. We have performed a 6-month stability test with dry ginger rhizome samples stored in a constant climate chamber in three different storage containers (uncovered glass container, glass container sealed with rubber stopper, plastic container). 6-gingerol contents were measured by HPLC method. The concentration of 6-gingerol decreased in all samples. In the sealed glass container, the decrease of 6-gingerol content was significantly lower than in the unsealed glass container and in the plastic container. These results demonstrate that storage conditions have a significant impact on the quality of ginger, which may also affect efficacy.},
	year = {2024},
	eissn = {1439-0221},
	orcid-numbers = {Tóth, Barbara/0000-0002-6086-8819; Matuz, Mária/0000-0002-7877-2399; Csupor, Dezső/0000-0002-4088-3333}
}

@article{MTMT:34496994,
	title = {The metabolic effect of Momordica charantia cannot be determined based on the available clinical evidence. a systematic review and meta-analysis of randomized clinical trials},
	url = {https://m2.mtmt.hu/api/publication/34496994},
	author = {Laczkó-Zöld, Eszter and Csupor-Löffler, Boglárka and Kolcsár, Edina-Blanka and Ferenci, Tamás and Nan, Monica and Tóth, Barbara and Csupor, Dezső},
	doi = {10.3389/fnut.2023.1200801},
	journal-iso = {FRONT NUTR},
	journal = {FRONTIERS IN NUTRITION},
	volume = {10},
	unique-id = {34496994},
	issn = {2296-861X},
	abstract = {Several studies have shown that Momordica charantia L. (Cucurbitaceae, bitter melon) has beneficial effects on metabolic syndrome (MetS) parameters and exerts antidiabetic, anti-hyperlipidemic, and anti-obesity activities. Since the findings of these studies are contradictory, the goal of this systematic review and meta-analysis was to assess the efficacy of bitter melon in the treatment of metabolic syndrome, with special emphasis on the anti-diabetic effect. Embase, Cochrane, PubMed, and Web of Science databases were searched for randomized controlled human trials (RCTs). The meta-analysis was reported according to the PRISMA statement. The primary outcomes of the review are body weight, BMI, fasting blood glucose, glycated hemoglobin A1c, systolic blood pressure, diastolic blood pressure, serum triglyceride, HDL, LDL, and total cholesterol levels. Nine studies were included in the meta-analysis with 414 patients in total and 4–16 weeks of follow-up. In case of the meta-analysis of change scores, no significant effect could be observed for bitter melon treatment over placebo on fasting blood glucose level (MD = −0.03; 95% CI: −0.38 to 0.31; I 2 = 34%), HbA1c level (MD = −0.12; 95% CI: −0.35 to 0.11; I 2 = 56%), HDL (MD = −0.04; 95% CI: −0.17 to 0.09; I 2 = 66%), LDL (MD = −0.10; 95% CI: −0.28 to 0.08; I 2 = 37%), total cholesterol (MD = −0.04; 95% CI: −0.17 to 0.09; I 2 = 66%,), body weight (MD = −1.00; 95% CI: −2.59–0.59; I 2 = 97%), BMI (MD = −0.42; 95% CI: −0.99–0.14; I 2 = 95%), systolic blood pressure (MD = 1.01; 95% CI: −1.07–3.09; I 2 = 0%) and diastolic blood pressure levels (MD = 0.24; 95% CI: −1.04–1.53; I 2 = 0%). Momordica treatment was not associated with a notable change in ALT, AST, and creatinine levels compared to the placebo, which supports the safety of this plant. However, the power was overall low and the meta-analyzed studies were also too short to reliably detect long-term metabolic effects. This highlights the need for additional research into this plant in carefully planned clinical trials of longer duration.},
	year = {2024},
	eissn = {2296-861X},
	orcid-numbers = {Ferenci, Tamás/0000-0001-6791-3080; Tóth, Barbara/0000-0002-6086-8819; Csupor, Dezső/0000-0002-4088-3333}
}

@article{MTMT:34398458,
	title = {Tea, kávé, csokoládé: finomak és egészségesek},
	url = {https://m2.mtmt.hu/api/publication/34398458},
	author = {Tóth, Barbara},
	journal-iso = {GYÓGYSZERTÁRI PRACTICUM NOVUM},
	journal = {GYÓGYSZERTÁRI PRACTICUM NOVUM},
	volume = {27},
	unique-id = {34398458},
	issn = {1789-9478},
	year = {2023},
	pages = {8-10},
	orcid-numbers = {Tóth, Barbara/0000-0002-6086-8819}
}

@article{MTMT:34398456,
	title = {Gyógynövények a bélben},
	url = {https://m2.mtmt.hu/api/publication/34398456},
	author = {Tóth, Barbara},
	journal-iso = {GYÓGYSZERTÁRI PRACTICUM NOVUM},
	journal = {GYÓGYSZERTÁRI PRACTICUM NOVUM},
	volume = {27},
	unique-id = {34398456},
	issn = {1789-9478},
	year = {2023},
	pages = {7-9},
	orcid-numbers = {Tóth, Barbara/0000-0002-6086-8819}
}

@article{MTMT:34398454,
	title = {Máriatövis. Nemcsak májvédelemre},
	url = {https://m2.mtmt.hu/api/publication/34398454},
	author = {Tóth, Barbara},
	journal-iso = {GYÓGYSZERTÁRI PRACTICUM NOVUM},
	journal = {GYÓGYSZERTÁRI PRACTICUM NOVUM},
	volume = {27},
	unique-id = {34398454},
	issn = {1789-9478},
	year = {2023},
	pages = {10-11},
	orcid-numbers = {Tóth, Barbara/0000-0002-6086-8819}
}

@article{MTMT:34398452,
	title = {Kurkuma. Fűszernövényből gyógyszer},
	url = {https://m2.mtmt.hu/api/publication/34398452},
	author = {Tóth, Barbara},
	journal-iso = {GYÓGYSZERTÁRI PRACTICUM NOVUM},
	journal = {GYÓGYSZERTÁRI PRACTICUM NOVUM},
	volume = {27},
	unique-id = {34398452},
	issn = {1789-9478},
	year = {2023},
	pages = {13-15},
	orcid-numbers = {Tóth, Barbara/0000-0002-6086-8819}
}

@article{MTMT:34398451,
	title = {Mire jó a C-vitamin?},
	url = {https://m2.mtmt.hu/api/publication/34398451},
	author = {Tóth, Barbara},
	journal-iso = {GYÓGYSZERTÁRI PRACTICUM NOVUM},
	journal = {GYÓGYSZERTÁRI PRACTICUM NOVUM},
	volume = {27},
	unique-id = {34398451},
	issn = {1789-9478},
	year = {2023},
	pages = {10-12},
	orcid-numbers = {Tóth, Barbara/0000-0002-6086-8819}
}

@article{MTMT:34398450,
	title = {A bélmikrobiom és a gyógynövények},
	url = {https://m2.mtmt.hu/api/publication/34398450},
	author = {Tóth, Barbara},
	journal-iso = {STUD & PRACT},
	journal = {STUDIUM & PRACTICUM: FÜGGETLEN GYÓGYSZERÉSZETI FOLYÓIRAT},
	volume = {17},
	unique-id = {34398450},
	issn = {1788-6996},
	year = {2023},
	pages = {4-5},
	orcid-numbers = {Tóth, Barbara/0000-0002-6086-8819}
}

@article{MTMT:34398449,
	title = {Máriatövis, régóta ismert gyógynövények újabb hatásai},
	url = {https://m2.mtmt.hu/api/publication/34398449},
	author = {Tóth, Barbara},
	journal-iso = {STUD & PRACT},
	journal = {STUDIUM & PRACTICUM: FÜGGETLEN GYÓGYSZERÉSZETI FOLYÓIRAT},
	volume = {17},
	unique-id = {34398449},
	issn = {1788-6996},
	year = {2023},
	pages = {8-9},
	orcid-numbers = {Tóth, Barbara/0000-0002-6086-8819}
}